Genetic Mutation Screen in Early Non--Small-Cell Lung Cancer (NSCLC) Specimens

Bar, Jair; Damianovich, Maya; Hout Siloni, Goni; Dar, Erel; Cohen, Yoram; Perelman, Marina; Nun, Alon Ben; Simansky, David; Yellin, Alon; Urban, Damien; Onn, Amir
March 2014
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p159
Academic Journal
No abstract available.


Related Articles

  • Updates in Non-Small Cell Lung Cancer. Walker, Suzanne // Clinical Journal of Oncology Nursing;Aug2008, Vol. 12 Issue 4, p587 

    Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and...

  • Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer. Bulk, Etmar; Jun Yu; Hascher, Antje; Koschmieder, Steffen; Wiewrodt, Rainer; Krug, Utz; Timmermann, Bernd; Marra, Alessandro; Hillejan, Ludger; Wiebe, Karsten; Berdel, Wolfgang E.; Schwab, Albrecht; Müller-Tidow, Carsten // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Alterations of Eph receptor tyrosine kinases are frequent events in human cancers. Genetic variations of EPHB6 have been described but the functional outcome of these alterations is unknown. The current study was conducted to screen for the occurrence and to identify functional consequences of...

  • KRAS Mutated Non-Small Cell Lung Cancer: A Distinct Disease Entity? Mellema, Wouter W.; Heideman, Daniëlle A. M.; Smit, Egbert F.; Thunnissen, Erik // Current Medical Literature: Lung Cancer;2013, Vol. 6 Issue 3, p63 

    The article discusses the biology of KRAS mutation and its biological behavior in respect to chemotherapy and outcome to determine whether KRAS-mutated non-small-cell-lung carcinoma (NSCLC) can be considered as a distinct form of lung cancer. It provides perspectives of treatment of patients who...

  • Early palliative care provides QOL benefits in NSCLC.  // PharmacoEconomics & Outcomes News;10/2/2010, Issue 613, p11 

    The article discusses research on improving the quality of life (QOL) of patients with non-small cell lung cancer (NSCLC) by giving early palliative care, which references the study "Early Palliative Care for Patients With Metastatic Non-Small-Cell Lung Cancer," by J. S. Temel et al.

  • Lung Cancer: Are we up to the Challenge? Esposito, Luca; Conti, Daniele; Ailavajhala, Ramyasri; Khalil, Nansie; Giordano, Antonio // Current Genomics;Nov2010, Vol. 11 Issue 7, p513 

    Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the...

  • Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. O'Toole, Sandra A.; Bing Yu; Cooper, Wendy // Journal of OncoPathology;Mar2014, Vol. 2 Issue 1, p63 

    The clinical importance of molecular testing for Epidermal Growth Factor Receptor (EGFR) mutations and ALK gene rearrangements in non-small cell lung cancer (NSCLC) is widely recognized. As most patients with NSCLC present with advanced stage disease not suitable for surgical resection, only...

  • Squamous Cell Carcinoma of the Lung: Pattern of Epidermal Growth Factor Receptor Mutation Distribution in Different Populations: A Summary. Wiwanitkit, Viroj // Lung;Sep/Oct2006, Vol. 184 Issue 5, p301 

    The article presents a study on lung squamous cell carcinoma and the epidermal growth factor receptor (EGFR) as its potential screening biomarkers to detect early stages of non-small-cell lung cancer. It summarizes studies on allele frequencies and polymorphism of the EGFR. Reports showed the...

  • Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy. Inoue, Akira; Nukiwa, Toshihiro // PLoS Medicine;Jan2005, Vol. 2 Issue 1, p20 

    Discusses gene mutations in lung cancer and the success of molecular therapy. Information on the process of molecular therapy for non-small-cell lung cancer (NSCLC); Description of the epidermal growth factor receptor gene mutations in NSCLC; Information on the therapeutic implications of...

  • Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ferté, C.; Besse, B.; Dansin, E.; Parent, F.; Buisine, M.-P.; Copin, M.-C.; Penel, N.; Soria, J.-C. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1385 

    A letter to the editor is presented which discusses the status of the KRAs mutations in the non-small-cell lung cancer (NSCLC) patients along with the effectiveness of the anti-epidermal growth factor receptor (EGFR) antibodies.

  • Crizotinib.  // Reactions Weekly;Oct2015, Vol. 1573 Issue 1, p81 

    The article presents a case study of 7 patients who developed anaplastic lymphoma kinase (ALK) mutations leading to disease progression while receiving treatment for non-small cell lung cancer (NSCLC).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics